Twist Bioscience Q3 Revenue Hits $118M Record But Overvaluation Concerns Mount

The Quick Take

• Twist Bioscience Q3 revenue hit $118M record while targeting EBITDA breakeven
• Analysts question if TWST's valuation premium is justified amid profitability pivot
• Synthetic biology platform diversification creates growth upside but complicates modeling

Twist Bioscience Corporation delivered record Q3 2026 revenue of $118 million, representing robust growth in its synthetic biology and DNA synthesis platform, yet analysts are raising concerns about whether the stock's current valuation adequately reflects execution risk. The company simultaneously announced an adjusted EBITDA breakeven goal, signaling a pivot toward profitability discipline that has become a prerequisite for sustainable capital market support in the current high-rate environment. TWST shares have attracted speculative growth premium typical of platform biology companies with capital-intensive manufacturing buildouts.

The core valuation debate centers on whether Twist's synthetic DNA platform can achieve the economies of scale necessary to justify a premium multiple. Synthetic biology has attracted significant investor enthusiasm but faces the practical challenge of converting R&D milestones into recurring, predictable revenue streams. TWST's customer base spans pharma, agricultural biotech, and industrial biology, creating revenue diversification but also making growth trajectory harder to model. The EBITDA breakeven commitment suggests management recognizes that growth alone no longer commands the multiple it once did in the current rate cycle.

For Indian investors and global biotech funds tracking the synthetic biology sector, TWST's pivot toward profitability is a signal worth monitoring. The US synthetic biology market remains a key bellwether for the broader computational biology investment thesis that is gaining traction in Indian deep-tech venture capital. Key variables include sequential revenue growth in the next two quarters and whether Twist can demonstrate EBITDA margin trajectory alongside its top-line records before institutional patience runs thin on the profitability timeline.

Synthesized from 1 source.